[go: up one dir, main page]

BR9810706A - Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento - Google Patents

Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento

Info

Publication number
BR9810706A
BR9810706A BR9810706-2A BR9810706A BR9810706A BR 9810706 A BR9810706 A BR 9810706A BR 9810706 A BR9810706 A BR 9810706A BR 9810706 A BR9810706 A BR 9810706A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
itching
mammal
need
Prior art date
Application number
BR9810706-2A
Other languages
English (en)
Inventor
John J Farrar
An-Chih Chang
Virendra Kumar
Wei Yuan Zhang
Alan Cowan
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/892,599 external-priority patent/US5760023A/en
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of BR9810706A publication Critical patent/BR9810706A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

"PROCESSO PARA A PREVENçãO OU TRATAMENTO DO PRURIDO EM UM MAMìFERO EM NECESSIDADE DE TAL PREVENçãO OU TRATAMENTO". Formulações farmacêuticas anti-pruríticas que contêm compostos de agonista capa e processos de prevenção ou tratamento de prurido em um mamífero com as formulações anti-pruríticas.
BR9810706-2A 1997-07-14 1998-06-19 Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento BR9810706A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/892,599 US5760023A (en) 1997-07-14 1997-07-14 Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US09/064,695 US5869521A (en) 1997-07-14 1998-04-22 Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
PCT/US1998/012789 WO1999003459A1 (en) 1997-07-14 1998-06-19 Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Publications (1)

Publication Number Publication Date
BR9810706A true BR9810706A (pt) 2000-08-08

Family

ID=26744793

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810706-2A BR9810706A (pt) 1997-07-14 1998-06-19 Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento

Country Status (10)

Country Link
US (3) US6004964A (pt)
EP (1) EP0996434A4 (pt)
JP (1) JP2003526594A (pt)
BR (1) BR9810706A (pt)
CA (1) CA2288828A1 (pt)
IL (1) IL132363A (pt)
MX (1) MXPA99011298A (pt)
NO (1) NO996353L (pt)
NZ (1) NZ500438A (pt)
WO (1) WO1999003459A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU738743B2 (en) * 1996-11-25 2001-09-27 Toray Industries, Inc. Antipruritic
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
GB0129267D0 (en) * 2001-12-06 2002-01-23 Syngenta Ltd Fungicides
US20060105008A1 (en) * 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US7639921B2 (en) * 2002-11-20 2009-12-29 Lg Electronics Inc. Recording medium having data structure for managing reproduction of still images recorded thereon and recording and reproducing methods and apparatuses
GB0227554D0 (en) * 2002-11-26 2002-12-31 Syngenta Ltd Fungicides
GB0227555D0 (en) * 2002-11-26 2002-12-31 Syngenta Ltd Fungicides
GB0227558D0 (en) * 2002-11-26 2002-12-31 Syngenta Ltd Fungicides
GB0227556D0 (en) * 2002-11-26 2002-12-31 Syngenta Ltd Fungicides
GB0227551D0 (en) 2002-11-26 2002-12-31 Syngenta Ltd Fungicides
GB0312863D0 (en) * 2003-06-04 2003-07-09 Syngenta Ltd Fungicides
GB0312864D0 (en) * 2003-06-04 2003-07-09 Syngenta Ltd Fungicides
ATE414516T1 (de) 2004-03-30 2008-12-15 Toray Industries Morphinanderivate als mittel gegen juckreiz
DK2081562T3 (en) 2006-09-20 2016-05-30 Univ Texas Method of administering volatile anesthetics for regional anesthesia and / or pain relief
KR20080067586A (ko) * 2007-01-16 2008-07-21 에스케이에너지 주식회사 분리막을 구비하고 있는 염료감응태양전지 및 그 제조방법
WO2009094459A1 (en) 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CN103554021A (zh) * 2013-11-25 2014-02-05 中国药科大学 一类茚酮四氢异喹啉衍生物、其制备方法及医药用途
CA3047325A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
CA3106995A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness, or dyspnea with nalbuphine compositions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
US4359476A (en) * 1981-04-09 1982-11-16 The Upjohn Company Adjacently substituted cycloalkane-amide analgesics
US4360531A (en) * 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US4466977A (en) * 1981-04-09 1984-08-21 The Upjohn Company N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics
US4438130A (en) * 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US4876269A (en) * 1986-09-10 1989-10-24 E. I. Du Pont De Nemours And Company Benoz-fused cycloalkane trans-1,2-diamine derivatives
ZA876778B (en) * 1986-09-10 1989-05-30 Du Pont Benzo-fused cycloalkane and oxa-and thia-,cycloalkane trans-1,2-diamine derivatives
DE3766335D1 (de) * 1986-09-17 1991-01-03 Zambeletti Spa L N-1-acylierte-(1-(phenyl- oder benzyl-))-1,2-aethylendiamine.
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
US4855316A (en) * 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
JPH02138254A (ja) * 1988-02-23 1990-05-28 Glaxo Group Ltd 複素環誘導体
PT89780A (pt) * 1988-02-23 1989-10-04 Glaxo Group Ltd Processo para a preparacao de derivados da tetrahidroisoquinolina
GB8804014D0 (en) * 1988-02-23 1988-03-23 Humphreys & Glasgow Ltd Synthesis gas production
PT90001B (pt) * 1988-03-16 1994-06-30 Zambeletti Spa L Processo para a preparacao de derivados heterociclicos de etilenodiamina
FI892468A (fi) * 1988-05-23 1989-11-24 Glaxo Group Ltd Piperazinderivat.
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
GB8824400D0 (en) * 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
AU626949B2 (en) * 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
GB8830219D0 (en) * 1988-12-23 1989-02-22 Zambeletti Spa L Novel compounds
US4906655A (en) * 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
US4965278A (en) * 1989-04-21 1990-10-23 Warner-Lambert Company 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents
EP0398720A3 (en) * 1989-05-18 1991-07-03 Glaxo Group Limited Piperazine derivatives
GB8916395D0 (en) * 1989-07-18 1989-09-06 Zambeletti Spa L Pharmaceuticals
JPH06511231A (ja) * 1991-05-21 1994-12-15 スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ ２−（ピロリジニル−１−メチル）−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用
CA2105072C (en) * 1992-01-23 1998-07-28 Hiroshi Nagase Morphinan derivative and its pharmaceutical applications
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
WO1994018165A1 (en) * 1993-02-12 1994-08-18 Pfizer Inc. Sulfonamide compounds as opioid k-receptor agonists
DE69424853T2 (de) * 1993-07-23 2000-10-05 Toray Industries, Inc. Morphinan-derivate und ihre medizinische verwendung
WO1996006078A1 (en) * 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5888494A (en) * 1996-03-12 1999-03-30 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
AU738743B2 (en) * 1996-11-25 2001-09-27 Toray Industries, Inc. Antipruritic
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5849762A (en) * 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates

Also Published As

Publication number Publication date
NZ500438A (en) 2001-11-30
WO1999003459A1 (en) 1999-01-28
EP0996434A4 (en) 2001-10-10
US6004964A (en) 1999-12-21
IL132363A0 (en) 2001-03-19
US6156769A (en) 2000-12-05
NO996353L (no) 2000-03-13
MXPA99011298A (es) 2004-10-28
JP2003526594A (ja) 2003-09-09
NO996353D0 (no) 1999-12-20
US6048860A (en) 2000-04-11
EP0996434A1 (en) 2000-05-03
IL132363A (en) 2004-02-19
CA2288828A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
BR9810706A (pt) Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9407752A (pt) Preparaçao de enzima aditivo detergente composiçao detergente processo para o tratamento de fibras lignocelulósicas
BR9913751A (pt) Uso de uma composição para proteção do tecido, e, método de tratar tecido para aperfeiçoar a sua estabilidade dimensional
BR9504224A (pt) Processo para prevenir que uma chamada ativa seja interrompida
BR9608405A (pt) Composto composi-Æo farmaceutica e processo para tratar um paciente que sofre de um distÚrbio fisiolÄgico
BR9407751A (pt) Processo para tratar metal e mistura líquida aquosa
BR9810712A (pt) Processo para a prevenção ou tratamento de prurido em um paciente
ES2194536T3 (es) Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
BR9909277A (pt) Compostos com atividade em receptores muscarìnicos
BR9407657A (pt) Processo e composiçao para o tratamento de tecido tingido
BR8804098A (pt) Compostos,composicoes e processo para reducao da fitotoxidez de plantas de cultura
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
BR0111116A (pt) Imitadores de trombopoietina
GEP20033044B (en) Method for Treating Atherosclerosis
BR9916544A (pt) Processo para tratamento de neoplasia em um indivìduo que necessita de tal tratamento, e, combinação
UA41355C2 (uk) Засіб для лікування нейро-сніду
BR9000838A (pt) Processo para dessecacao e abcisao de orgaos vegetais
BR9811839A (pt) Plasma sanguìneo universalmente aplicável
IL133952A0 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
PT1144365E (pt) Inibidores da adesao de celulas mediada por alfa4beta1
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.